SCHEMBL2174959

SCHEMBL2174959

COC(=O)CCOC(=O)C(C)=O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.52
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
MGAM O43451 1/20 0.42
GAA P10253 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
LMNA P02545 3/20 0.39
CA12 O43570 2/20 0.39
CA14 Q9ULX7 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 3/20 0.38
HSD17B10 Q99714 2/20 0.38
MAPT P10636 2/20 0.38
HTT P42858 1/20 0.38
TET2 Q6N021 1/20 0.35
BLM P54132 1/20 0.35
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12270505 0.83 THRB (0.52) TSHRKMT2AMEN1MGAMGAA
SCHEMBL28411109 0.83 THRB (0.52) TSHRKMT2AMEN1MGAMGAA
SCHEMBL2979211 0.81 TSHR (0.57) TSHRKMT2AMEN1MGAMGAA
SCHEMBL2175759 0.80 CYP1A2 (0.47) TSHRMGAMGAASIMGAM2
SCHEMBL12310163 0.77 TSHR (0.52) TSHRKMT2AMEN1MGAMGAA
SCHEMBL12088001 0.77 THRB (0.46) TSHRGAALMNAALDH1A1HSD17B10
SCHEMBL13217245 0.77 THRB (0.50) TSHRKMT2AMEN1MGAMGAA
SCHEMBL3453928 0.76 TSHR (0.57) TSHRKMT2AMEN1MGAMGAA
SCHEMBL4446601 0.76 TSHR (0.57) TSHRKMT2AMEN1MGAMGAA
SCHEMBL4446598 0.76 TSHR (0.57) TSHRKMT2AMEN1MGAMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2493467-B1 COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS HILLS PET NUTRITION INC (US) 2017-05-31 EP disclosed
EP-2519115-B1 COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF HILLS PET NUTRITION INC (US) 2017-02-15 EP disclosed
US-9173422-B2 Compositions including pyruvate for companion animals and methods of use thereof HILL'S PET NUTRITION, INC. (US) 2015-11-03 US disclosed
US-9011900-B2 Compositions including pyruvate for companion animals and methods of use thereof HILL'S PET NUTRITION, INC. (US) 2015-04-21 US disclosed
US-8999375-B2 Compositions including pyruvate for companion animals and methods of use thereof HILL'S PET NUTRITION, INC. (US) 2015-04-07 US disclosed
US-20120309828-A1 COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF HILL'S PET NUTRITION, INC. (US) 2012-12-06 US disclosed
US-20120309829-A1 COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF HILL'S PET NUTRITION, INC. (US) 2012-12-06 US disclosed
US-20120289598-A1 COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF HILL'S PET NUTRITION, INC. (US) 2012-11-15 US disclosed
EP-2519114-A1 COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF Hill's Pet Nutrition, Inc. (US) 2012-11-07 EP disclosed
EP-2519115-A1 COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF Hill's Pet Nutrition, Inc. (US) 2012-11-07 EP disclosed
EP-2493467-A1 COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF Hill's Pet Nutrition, Inc. (US) 2012-09-05 EP disclosed
WO-2011090676-A1 COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF HILL'S PET NUTRITION, INC. (US) 2011-07-28 WO disclosed
WO-2011082081-A1 COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF HILL'S PET NUTRITION, INC. (US) 2011-07-07 WO disclosed
WO-2011082080-A1 COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF HILL'S PET NUTRITION, INC. (US) 2011-07-07 WO disclosed
EP-1494659-B1 PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT CRITICAL THERAPEUTICS INC (US) 2005-10-12 EP disclosed
EP-1494659-A1 PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT Critical Therapeutics, Inc. (US) 2005-01-12 EP disclosed
US-20030232884-A1 New pharmaceutical formulation CRITICAL THERAPEUTICS, INC. 2003-12-18 US disclosed
WO-2003088955-A1 PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMINE AND LACTIC ACID OR A LACTIC ACID SALT CRITICAL THERAPEUTICS, INC. (US) 2003-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232884-A1 New pharmaceutical formulation LIPA, CEL, LDHA TSHR 3160/4885KMT2A 2430/4885MEN1 4296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.